Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 13, 2009

View Archived Issues

Phase II data disclosed for ABT-869 in the treatment of RCC and HCC

New atypical antipsychotic JNJ-37822681 enters phase II trial in schizophrenia

RESOLVE results: improved visual acuity in diabetic macular edema with ranibizumab

Benefit of phentermine/topiramate seen in type 2 diabetes patients in phase II trial

Pooled analysis shows saxagliptin beneficial in elderly type 2 diabetes patients

Prospective analysis supports triamcinolone acetonide in Hunner's ulcer subtype IC

Recent study supports use of alfuzosin in primary bladder neck obstruction

GPC Biotech provides update on merger with Agennix

Lpath reports phase I results for iSONEP in patients with wet AMD

Nerviano Medical Sciences reports results from phase I danusertib trial

NeuroSearch begins phase Ib ACR-325 study in Parkinson's disease dyskinesias

New compounds for the treatment of obesity claimed by University of Strathclyde

Novel TpoR agonists in early development at Shanghai Hengrui

Epigenomics initiates testing of mSEPT9 in plasma samples collected in PRESEPT study

AC Immune to utilize Bayer's florbetaben in phase I trial of AD vaccine ACI-24

AstraZeneca describes VLA-5 antagonists for the treatment of cancer

RXi Pharmaceuticals presents preclinical results from animal studies of sd-rxRNA

Plexxikon initiates dosing in phase I trial of first-in-class cancer drug PLX-3397

FDA advisory committee recommends approval of Pfizer's Selzentry in HIV

CardioPharma plans to submit NDA for CardiaPill polypill

Ipsen granted manufacturing, marketing and distribution rights to Braintree's BLI-800

MediGene completes recruitment in phase II trial of EndoTAG in breast cancer

Actelion initiates phase IIb study of ACT-128800 in multiple sclerosis

FDA issues complete response letter for Spectrum's sNDA for Fusilev

MacuCLEAR and Mystic complete phase Ib trial of MC-1101 in AMD

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...